C-MET As a Potential Therapeutic Target and Biomarker in Cancer

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2011 Dec 1

PMID 22128285

Citations 172

Authors

J Rafael Sierra

Ming-Sound Tsao

Affiliations

Soon will be listed here.

Abstract

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.

Citing Articles

Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective.

Mishra S, Kumari S, Husain N J Liq Biopsy. 2025; 6:100280.

PMID: 40027313 PMC: 11863890. DOI: 10.1016/j.jlb.2024.100280.

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET.

Ruffilli C, Roth S, Zelcer N, Moreau K Sci Rep. 2025; 15(1):504.

PMID: 39748066 PMC: 11696238. DOI: 10.1038/s41598-024-84217-2.

Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma.

Fu X, Huang J, Chen X, Xie D, Chen H, Liang Z Theranostics. 2025; 15(1):103-121.

PMID: 39744222 PMC: 11667235. DOI: 10.7150/thno.99588.

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors.

Lutimba S, Saleem B, Aleem E, Mansour M J Xenobiot. 2024; 14(4):1962-1987.

PMID: 39728413 PMC: 11676455. DOI: 10.3390/jox14040105.

References

Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y . Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008; 99(11):2280-5. PMC: 11159911. DOI: 10.1111/j.1349-7006.2008.00916.x. View

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T . Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011; 103(8):645-61. DOI: 10.1093/jnci/djr093. View

John T, Kohler D, Pintilie M, Yanagawa N, Pham N, Li M . The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin Cancer Res. 2010; 17(1):134-41. DOI: 10.1158/1078-0432.CCR-10-2224. View

Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K . Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2009; 68(2):198-203. DOI: 10.1016/j.lungcan.2009.05.022. View

Conrotto P, Corso S, Gamberini S, Comoglio P, Giordano S . Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene. 2004; 23(30):5131-7. DOI: 10.1038/sj.onc.1207650. View

Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, Hirata H . Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. Cancer Sci. 2011; 102(8):1602-4. DOI: 10.1111/j.1349-7006.2011.01970.x. View

Lee J, Han S, Cho H, Jennings B, Gerrard B, Dean M . A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000; 19(43):4947-53. DOI: 10.1038/sj.onc.1203874. View

Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E . Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992; 189(1):227-32. DOI: 10.1016/0006-291x(92)91548-5. View

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

10.

Schmidt L, Duh F, Chen F, Kishida T, Glenn G, Choyke P . Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997; 16(1):68-73. DOI: 10.1038/ng0597-68. View

11.

Huh C, Factor V, Sanchez A, Uchida K, Conner E, Thorgeirsson S . Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A. 2004; 101(13):4477-82. PMC: 384772. DOI: 10.1073/pnas.0306068101. View

12.

Park W, Dong S, Kim S, Na E, Shin M, Pi J . Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999; 59(2):307-10. View

13.

Seiden-Long I, Brown K, Shih W, Wigle D, Radulovich N, Jurisica I . Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. Oncogene. 2005; 25(1):91-102. DOI: 10.1038/sj.onc.1209005. View

14.

Liu C, Park M, Tsao M . Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 1992; 7(1):181-5. View

15.

Corso S, Comoglio P, Giordano S . Cancer therapy: can the challenge be MET?. Trends Mol Med. 2005; 11(6):284-92. DOI: 10.1016/j.molmed.2005.04.005. View

16.

Lengyel E, Prechtel D, Resau J, Gauger K, Welk A, Lindemann K . C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2004; 113(4):678-82. DOI: 10.1002/ijc.20598. View

17.

Smolen G, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H . Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006; 103(7):2316-21. PMC: 1413705. DOI: 10.1073/pnas.0508776103. View

18.

Park M, Dean M, Cooper C, Schmidt M, OBrien S, Blair D . Mechanism of met oncogene activation. Cell. 1986; 45(6):895-904. DOI: 10.1016/0092-8674(86)90564-7. View

19.

Furukawa T, DUGUID W, Kobari M, Matsuno S, Tsao M . Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol. 1995; 147(4):889-95. PMC: 1870999. View

20.

Aguirre Ghiso J, Alonso D, Farias E, Gomez D, de Kier Joffe E . Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem. 1999; 263(2):295-304. DOI: 10.1046/j.1432-1327.1999.00507.x. View